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Abstract
Context: Primary urethral cancer (PUC) is a rare cancer entity. Owing to the low incidence of
this malignancy, the main body of literature consists mainly of case reports, making evidence-
based management recommendations difficult.
Objective: To review reported disease management strategies of PUC and their impact on
oncological outcomes.
Evidence acquisition: A systematic research was performed according to the Preferred
Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement using Medline,
Scopus, and Web of Science, to find studies of the past 10 yr including 20 patients, and
investigating treatment strategies and their impact on outcomes of the three most frequent
histologies: urothelial carcinoma, adenocarcinoma, and squamous cell carcinoma.
Evidence synthesis: In localized PUC, penis-sparing surgery can be performed in males, while
in females, complete urethrectomy with surrounding tissue is advised to minimize recurrence
due to positive margins. Radiotherapy (RT) has worse survival and recurrence rates, as well as
more adverse effects, than surgery, limiting its use in genital-preserving therapy. Locally
advanced PUC should be treated with multimodal therapy, as monotherapies result in inferior
recurrence and survival rates. Extent of surgery is still undecided, favoring radical cyst
(oprostat)ectomy with total urethrectomy (RCU). Lymph node involvement is a predictor
of survival, highlighting the role of lymph node dissection for disease control and staging. RT
can improve survival in combination with surgery and/or chemotherapy (CHT). Neoadjuvant
platinum-based CHT can improve overall and recurrence-free survival. At recurrence, salvage
therapy with surgery and/or CHT can improve survival. Superficial urothelial carcinoma of the
prostatic urethra can be treated with transurethral resection. Stromal invasion often features
concomitant bladder cancer with a poor prognosis and requires RCU with or without systemic
preoperative CHT.
Conclusions: PUC is a rare malignancy with an often poor natural course, requiring a stage-
and gender-specific risk-based treatment strategy. The role of systematic perioperative CHT
and the extent of surgery are becoming more important.
Patient summary: In this review, we looked at the treatment options for primary urethral
cancer. We found that while an organ-confined disease can be managed with local resection,
growth beyond the organ border makes a combination of different treatment modalities, such
as surgery and systematic chemotherapy, necessary to improve outcomes.
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Primary urethral cancer (PUC) is a rare malignancy that
makes up <1% of all malignancies worldwide. It occurs
almost three times as often in males than in females, and
its incidence rises in the elderly (ie, >75 yr old) [1–4].
Suggested etiologies for PUC are chronic irritations of the
urethra due to catheterization, chronic inflammation sec-
ondary to infection, radiation, urethral diverticula, and
strictures [5–7]. An association between squamous cell
carcinoma (SCC) and genital lichen sclerosus is also
reported as a potential risk factor [8].
PUC has several histological subtypes arising from dif-
ferent cell types with potentially different biological and
clinical behavior, requiring varied therapeutic approaches.
The predominant histological type is urothelial carcinoma
(UC) and is present in 54–65% of cases, followed by SCC
(16–22%) and adenocarcinoma (AC; 10–16%). Other, rarer
histological types include melanoma or sarcoma. Subtypes
are not evenly distributed between genders, and their
different origins can be explained by different urethral
anatomies between the two sexes [1,3]. The differences
have led to recent proposals for a new histological classi-
fication of PUC [9]. There is no doubt today that the
diagnosis, therapy, and follow-up will depend on the his-
tological classification and anatomic specifications of each
tumor in the future. Until then, we try to develop individ-
ualized, risk-based, gender-specific strategies based on the
existing evidence.
Most publications on PUC were based on small patient
cohorts or case reports only. This results in limited knowl-
edge on the optimal management of PUC compared with
other malignancies. However, in recent years, larger, popu-
lation-based and multicentric studies were published, pro-
viding new insights into this rare malignancy with a vari-
able natural history. We aim to give an overview of the
current literature in context with the established knowl-
edge on PUC to help guide modern, optimized diagnosis and
clinical management.
2. Evidence acquisition
To find all English studies of the past 10 yr investigating the
therapeutic management of PUC, a systematic research
was conducted in December 2018 in several online data-
bases (PubMed, Cochrane, Scopus, and Web of Science)
with the following search terms: ((((therapy) OR manage-
ment) AND "last 10 years"[PDat])) AND (((urethral carci-
noma) OR urethral cancer) AND "last 10 years"[PDat]). We
included all original studies with a minimum of
20 patients. The minimum number of patients was chosen
to assess statistically valuable data without omitting
potential information on this disease. Studies had to focus
on SCC, transitional cell carcinoma, or AC as a primary
histology to provide a review of the most common patient
groups of this rare malignancy. Interventions necessary for
inclusion consisted of surgery, radiotherapy, and/or che-
motherapy (CHT). An additional, similar systematic searchwas performed to find all original articles reporting on the
diagnosis and treatment of UC of the prostatic urethra with
the following search terms: (((outcome) AND ((urothelial
carcinoma) OR transitional carcinoma)) AND prostatic ure-
thra) AND “last 10 years”[PDat]). Reported overall survival
(OS), cancer-specific survival (CSS), progression-free sur-
vival (PFS), and/or recurrence-free survival (RFS) were the
obligatory primary endpoints for inclusion. Studies inves-
tigating the same cohort were included, as long as new
evidence on outcome was provided. The Newcastle-Ottawa
Score was used to assess risk of bias across the studies
[10]. Studies with a score of 6 were considered to be of
“high quality”.
3. Evidence synthesis
A total of 12 studies with 7853 patients were included
according to the statement of Preferred Reporting Items
for Systematic Review and Meta-analysis (PRISMA) proto-
cols (Fig. 1, and Tables 1 and 2) [11–20]. Two large multi-
centric studies reported on the same cohort [14,15]. Three
other studies were of single-center nature [13,16,21]. The
rest of the studies investigated cohorts of the Surveillance,
Epidemiology, and End Results (SEER) database or of the
National Cancer Database (NCDB). A proposal of clinical
disease management in consolidation of our findings and
the guidelines of the European Association of Urology (EAU)
and National Comprehensive Cancer Network (NCCN) is
presented in Fig. 2 [22,23].
3.1. Diagnostic evaluation and staging
Clinicopathological staging and grading for PUC adheres to
the classification given by the Union for International Can-
cer Control in 2017 and the World Health Organization in
2016 (Table 3) [24,25]. Approximately 50% of patients have
locally advanced disease when they become symptomatic
[26], presenting with macrohematuria, urethral bleeding,
an extraurethral mass, and subvesical obstruction. Urine
cytology has limited sensitivity of 50–80%, depending on
the underlying histology [27]. Transurethral resection (TUR)
or a cold biopsy is necessary for a histological confirmation
[28]. In addition, cystoscopy of the bladder should be per-
formed to detect concomitant bladder tumor, as urethral
cancer could also be originating from the bladder through
micrometastasis [29]. Indeed, approximately 2–5% of
patients with superficial and 40–60% with muscle-invasive
bladder cancer develop urethral cancer later on [29]. In
contrast, Gakis et al [30] reported one case (0.9%) of sec-
ondary bladder cancer 41 mo after initial therapy for PUC.
Enlarged regional lymph nodes (LNs) are likely to rep-
resent metastatic disease (84%), making assessment of
disease extent with pelvic magnetic resonance imaging
for local staging obligatory [13,31,32]. Additionally, LN
biopsy is proposed by the NCCN as well. Further, patients
with invasive disease should receive computer tomogra-
phy of the abdomen and thorax, or chest x-ray to detect
distant metastasis [22].
Fig. 1 – Flow chart for article selection process to analyze the current disease management of primary urethral cancer according to the Preferred
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.
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3.2.1. Surgical approach in men and women
While in the past, partial penectomy was the predominant
option for treatment of PUC in men, today, current guide-
lines agree that surgical preservation of the penis can beachieved while maintaining good local cancer control
[22,23,33]. This strategy has, indeed, become the preferred
option. A distal location of the primary tumor has been
shown to result in better survival [14,15,17]. Of note, the
NCCN always recommends urethrectomy in men with or
without cystoprostatectomy if the tumor is located in the
Table 1 – Baseline characteristics, treatment, and outcomes of included studies investigating primary urethral cancer.
Author and
year
N Study design Histology, n (%) Stage, n (%) Treatment Survival rate (%) Median survival
time (mo)
Important findings NOS
Cahn et al
(2017) [11]
1749 PUC pts. with locally
advanced PUC (NCDB
database)
2004–2013
SCC: 513 (29.3)
UC:848 (48.5)
AC: 388 (22.2)
NR -Local excision or CHT or RT
-RCU  RT
-MMT: RCU + CHT  RT
NR OS for monotherapy:
30.1
OS for RCU  RT: 42.6
OS for MMT: 33.4
-No difference in outcome in OS
depending on type of monotherapy
-In MMT patients only, OS
improved in patients with UC
histology (HR 0.61; 95% CI = 0.45–
0.83; p = 0.0016)
8
Champ et al
(2012) [12]
359 Female pts. with
urethral or
paraurethral cancer
(SEER database)
1983–2008
SCC: 92 (25.6)
UC: 85 (23.7)
AC: 133 (37.0)
Other: 49 (13.7)
T1–2: 177 (49.3)
T3–4: 179 (49.9)
Tx: 3 (0.8)
N0: 214 (66.9)
M0: 159 (100)
-Surgery (ablation, resection,
none)
-RT (neoadjuvant, adjuvant,
combined)
5-yr OS: 43%
10-yr OS: 32%
5-yr CSS: 53%
10-yr CSS: 46%
NR -Surgery only was associated with
longer CSS (HR 0.60; 95% CI = 0.39–
0.93)
-(Additional) RT and extent of
surgery had no effect on CSS
5
Dayyani et al
(2013) [13]
44 PUC pts. treated with
CHT and/or surgery
2005–2009a
SCC: 17(39)
UC: 8 (19)
AC: 13 (30)
Other: 6 (13)
T1–2: 1 (2)
T3–4: 43 (98)
N0: 18 (41)
M0: 57 (84)
-Surgery + CHT (urethrectomy,
RCU, LND, APE, penectomy,
prostatectomy, other)
-CHT (CGI, Gem FLP, ITP, MVAC,
other)
-CHT + surgery
-Other
3-yr-RFS in platinum-based
CHT: 50%
OS: 31.7
OS in platinum-based
CHT + RCU: 25.6
-OS of CHT patients improved by
surgery (HR 0.4; 95% CI = 0.18–
0.87; p = 0.02)
6
Gakis et al
(2015) [14]
124 Nonmetastatic PUC pts.
1993–2012b
Only reported for
subgroup with
perioperative CHT
(n = 39):
SCC: 11 (28.2)
UC: 17 (43.6)
AC: 6 (15.4)
Mixed: 3 (7.7)
Other: 2 (5.1)
cT2N0: 98 (79.0)
cT3 and/or cN+:
26 (21.0)
-Surgery only
-Neoadjuvant CHT
-Neoadjuvant RCT + adjuvant
CHT
-Adjuvant CHT
CHT regime:
-Mitomycin  5-FU
-Cisplatinum-based
-Gemcitabine based
-Other
3-yr OS in CHT: 61%
3-yr OS in  cT3 and/or cN
+:
CHT + RCU: 100%
RCT: 100%
CHT + RCU: 20%
Surgery only: 50%
For patients with objective
response to CHT + RCU:
3-yr OS in stable disease:
100%
3-yr OS in progressive
disease: 58.3%
NR -Improved 3-yr RFS (RR: 0.14; p
= 0.022) and OS (RR: 0.10; p
= 0.024) with neoadjuvant therapy
in locally advanced patients
8
Gakis et al
(2018) [15]
139 Nonmetastatic PUC pts.
(prospective database)
1993–2012b
SCC: 55 (39.6)
UC: 71 (51.0)
AC: 10 (7.2)
Other: 3 (2.2)
pT2: 84 (60.4)
pT3: 38 (27.4)
pTx: 17(12.2)
pN0: 48 (34.5)
Surgery (endoscopic, RCU and/
or [partial] urethrectomy,
prostatectomy)  LND
RCT (40–45 Gy to pelvis + 20–
24 Gy to primary tumor) CHT
CHT (neoadjuvant, adjuvant,
both)
3-yr OS:
-No recurrence: 86.5%
-Solitary or concomitant
recurrence: 74.5%
-Extraurethral recurrence:
48.2%
3-yr OS in patients with ST:
-RCT: 84.9%
-Surgery: 71.6%
-None: 38.0%
NR -OS for patients with ST (surgery or
RCT), comparable with patients
with no recurrence (p = 0.65)
-In univariable analysis, OS
improved for patients with ST
(surgery or RCT) vs without
surgery/RCT ST (overall p < 0.045);
no difference in OS in surgery ST vs
RCT ST
8
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Table 1 (Continued )
Author and
year
N Study design Histology, n (%) Stage, n (%) Treatment Survival rate (%) Median survival
time (mo)
Important findings NOS
Peyton et al
(2018) [16]
39 Female PUC pts.
2003–2017a
SCC: 5 (13)
UC: 11 (28)
AC: 22 (56)
Other: 1 (3)
Tis: 2 (5)
T1–2: 13 (33)
T3–4: 24 (62)
N0/Nx: 27 (69)
M0/Mx: 36 (92)
-Surgery (local excision, RCU)
 adjuvant CHT/RT/RCT
-Neoadjuvant RCT + RCU
-CHT
-RCT
Therapy regimes:
-Neoadjuvant: Cis  etoposide
+ RT; Gem/Cis + RT; paclitaxel
+ RT; 5-FU/mitomycin + RT
-Adjuvant: RT; Gem/Cis; Carbo
 Taxol  RT; Cis  5-FU + RT;
5-FU/oxaliplatin;
pembrolizumab; RCU
urethrectomy
NR Nonmetastatic pts.:
OS in  T1: 99
OS in  T2:
-Overall: 36
-UC: 18
-SCC: 7
-AC: 48
-MMT: 36
-Non-MMT: 16
RFS in  T1: Not
reached
RFS in  T2:
-Overall: 46
-MMT 58 mo
-Non-MMT: 16 mo
-No difference in OS and RFS with
the use of MMT compared with
monotherapy
Patients with recurrence or
progression:
-No difference in OS with ST
-No difference in OS and RFS in
patients with MMT compared with
non-MMT
6
Rabbani
(2011) [17]
2065 Male PUC pts.
(SEER database)
1973–2006
SCC: 245 (11.9)
UC: 1603 (77.6)
AC: 103 (5.0)
Other: 114 (5.5)
Ta/cis: 871 (42.2)
T1–2: 806 (39.0)
T3–4: 184 (8.9)
Tx: 204 (9.9)
N0: 1480 (71.7)
M0/Mx: 1966
(95.2)
-Surgery (none/biopsy,
ablation, simple excision,
radical resection, not otherwise
specified, and unknown)
-RT (none, external beam
radiation alone, brachytherapy,
combination of external beam
and brachytherapy, not
otherwise specified, and
unknown)
5-yr OS: 46.2
10-yr OS: 29.3
NR Multivariable analysis:
-OS and CSS improved with RCU
compared with no intervention/
biopsy (HR 1.56; p < 0.001/HR
1.66; p = 0.002)
-CSS improved with surgery alone
compared with RT alone or no
treatment (p = 0.001/p < 0.001)
-CSS improved with surgery + RT
compared with no surgery and no
RT (p = 0.017)
7
Son et al
(2018) [18]
2614 Nonmetastatic PUC pts.
with surgery and/or RT
(NCDB)
2004–2013
SCC: 622 (24)
UC: 1509 (58)
AC: 306 (12)
Other: 177 (7)
T0–1: 724 (28)
T2: 515 (19)
T3–4: 570 (21.8)
Tx: 805 (31)
N0: 1635 (62)
-Surgery (local or radical)
-RT  external beam
radiotherapy (median 60 Gy
to pelvis)  CHT
-Surgery + RT (median
30.6 Gy)
-No local therapy
3-yr OS:
-All pts. 54%
-SCC: 41%
-UC: 33%
-AC: 42%
-No local treatment: 37%
-Surgery: 58%
-RT  CHT: 44%
-Surgery + RT: 57%
3-yr OS in T1–2 N0:
Surgery: 28%
Surgery + RT: 60%
RT: 42%
3-yr OS in T3–4 and/or N+:
No local therapy: 28%
RT: 44%
Surgery + RT: 52%
-OS in all treatment types was
associated with CHT and RCT
(overall p < 0.05)
-Absence of local therapy was an
independent factor for worse OS
(no HR reported)
-Postoperative RT was an
independent factor for improved
OS in general (HR 0.77) and locally
advanced patients (HR 0.58), but
stratified to histology only in UC
(HR 0.45) and AC (see below) (all p
 0.01)
-In early stage, there was no
difference in OS according to
treatment
-In AC patients, OS was better with
RT or surgery + RT compared with
surgery alone (HR 0.20 and 0.27),
but OS was worse with
chemotherapy (HR 3.43; all
p  0.01)
8
E
 U
 R
 O
 P
 E
 A
 N
 U
 R
 O
 L
 O
 G
 Y
 F
 O
 C
 U
 S
 5
 (
 2
 0
 1
 9
 )
 7
 2
 2
 –
 7
 3
 4
726
Ta
b
le
1
(C
on
ti
n
u
ed
)
A
u
th
or
an
d
ye
ar
N
St
u
d
y
d
es
ig
n
H
is
to
lo
gy
,n
(%
)
St
ag
e,
n
(%
)
Tr
ea
tm
en
t
Su
rv
iv
al
ra
te
(%
)
M
ed
ia
n
su
rv
iv
al
ti
m
e
(m
o)
Im
p
or
ta
n
t
fi
n
d
in
gs
N
O
S
W
ei
et
al
(2
01
7)
[1
9]
45
3
PU
C
p
ts
.(
SE
ER
d
at
ab
as
e)
20
04
–
20
13
SC
C
:
16
5
(3
6.
4)
U
C
:
20
2
(4
4.
6)
A
C
:
86
(1
9)
T0
–
1:
13
4
(2
9.
6)
T2
:
11
5
(2
5.
6)
T3
–
4/
x:
20
3
(4
4.
8)
N
0:
31
3
(6
9.
1)
M
0:
37
7
(8
3.
2)
-S
u
rg
er
y
-R
T
-S
u
rg
er
y
+
R
T
5-
yr
C
SS
in
m
en
/w
om
en
:
52
.5
2/
44
.8
9
5-
yr
O
S
in
m
en
/w
om
en
:
38
.5
2/
35
.8
8
C
SS
m
en
/w
om
en
:
63
/
52 O
S
m
en
/w
om
en
:
32
/3
9
-S
ig
n
ifi
ca
n
tl
y
be
tt
er
O
S
fo
r
w
om
en
w
h
en
su
rg
er
y
is
p
er
fo
rm
ed
(H
R
0.
56
;
p
=
0.
03
)
8
A
C
=
ad
en
oc
ar
ci
n
om
a;
C
ar
bo
=
ca
rb
op
la
ti
n
;
C
G
I=
ci
sp
la
ti
n
,
ge
m
ci
ta
bi
n
e,
an
d
if
os
fa
m
id
e;
C
H
T
=
ch
em
ot
h
er
ap
y;
C
I=
co
n
fi
d
en
ce
in
te
rv
al
;
C
is
=
ci
sp
la
ti
n
;
C
SS
=
ca
n
ce
r-
sp
ec
ifi
c
su
rv
iv
al
;
5-
FU
=
5-
fl
u
or
ou
ra
ci
l;
G
em
=
ge
m
ci
ta
bi
n
e;
G
em
-F
LP
=
ge
m
ci
ta
bi
n
e,
5-
fl
u
or
ou
ra
ci
l,
le
u
co
vo
ri
n
,
an
d
ci
sp
la
ti
n
;
H
R
=
h
az
ar
d
ra
ti
o;
IT
P
=
if
os
fa
m
id
e,
p
ac
li
ta
xe
l,
an
d
ci
sp
la
ti
n
;
LN
D
=
ly
m
p
h
n
od
e
d
is
se
ct
io
n
;
M
M
T
=
m
u
lt
im
od
al
th
er
ap
y
(c
on
si
st
in
g
of
a
co
m
bi
n
at
io
n
of
su
rg
er
y,
ch
em
ot
h
er
ap
y,
an
d
ra
d
io
th
er
ap
y)
;
M
V
A
C
=
m
et
h
ot
re
xa
te
,
vi
n
bl
as
ti
n
e,
d
ox
or
u
bi
ci
n
,
an
d
ci
sp
la
ti
n
;
N
C
D
B
=
N
at
io
n
al
C
an
ce
r
D
at
ab
as
e;
N
O
S
=
N
ew
ca
st
le
-O
tt
aw
a
Sc
or
e;
N
R
=
n
ot
re
p
or
te
d
;
O
S
=
ov
er
al
ls
u
rv
iv
al
;p
ts
.=
p
at
ie
n
ts
;P
U
C
=
p
ri
m
ar
y
u
re
th
ra
lc
an
ce
r;
R
C
T
=
ra
di
oc
h
em
ot
h
er
ap
y;
RC
U
=
ra
d
ic
al
cy
st
(o
p
ro
st
at
)e
ct
om
y
w
it
h
to
ta
lu
re
th
re
ct
om
y;
R
FS
=
re
cu
rr
en
ce
-f
re
e
su
rv
iv
al
;R
R
=
ri
sk
ra
ti
o;
R
T
=
ra
d
io
th
er
ap
y;
SC
C
=
sq
u
am
ou
s
ce
ll
ca
rc
in
om
a;
SE
ER
=
Su
rv
ei
ll
an
ce
,E
p
id
em
io
lo
gy
an
d
En
d
R
es
u
lt
s;
Ta
xo
l=
p
ac
li
ta
xe
l;
U
C
=
u
ro
th
el
ia
l
ca
rc
in
om
a.
a
Si
n
gl
e-
in
st
it
u
ti
on
al
st
u
d
y.
b
M
u
lt
i-
in
st
it
u
ti
on
al
st
u
d
y
of
10
cl
in
ic
al
ce
n
te
rs
;
a
p
ro
sp
ec
ti
ve
d
at
ab
an
k
w
as
u
se
d
fo
r
re
tr
os
p
ec
ti
ve
as
se
ss
m
en
t.
E U R O P E A N U R O L O G Y F O C U S 5 ( 2 0 1 9 ) 7 2 2 – 7 3 4 727bulbous urethra [23]. While several retrospective series
have reported no recurrence after local excision in males,
positive margins have been found to increase the risk of
recurrence. Therefore, as recommended by the EAU guide-
lines, complete circumferential excision, especially of the
proximal margin, should be performed in combination with
a perineal urethrostomy [22,34].
In contrast, in women, current guidelines recommend
removal of the complete urethra with a wide margin of
periurethral tissue and the bulbocavernous muscle up to the
bladder neck and pelvic bone [22,23,35], since a simulta-
neous proximal and distal tumor location results in shorter
PFS [36,37]. In these cases, a suprapubic urostomy or pouch
is necessary for urinary diversion. While partial urethrect-
omy or TUR in women can be performed, recurrence rates
were up to 60% and survival decreased significantly [38]. In
case of female PUC in urethral diverticula, diverticulectomy
has been proposed in a recent review [39]. However, the low
number of assessed patients was suboptimal for reporting
relevant outcomes; 50% of patients with T2 stage (n = 3)
were disease free after a mean follow-up of 66 mo. Impor-
tance of thorough surgical excision of the primary lesion is
the key to local disease control. Thus, partial urethrectomy
should be considered only if complete tumor resection can
be guaranteed, as PFS and OS are the most important end-
points in this disease with limited salvage therapeutic
options in case of failure. Interestingly, in contrast to EAU
guidelines, the NCCN does not recommend bladder-sparing
surgery in women at all [23].
3.2.2. Radiotherapy in female patients
Local radiotherapy (RT) with a median of 50–65 Gy
through external beam therapy or brachytherapy can pro-
vide an alternative to surgery in women [37]. While treat-
ment is possible and 5-yr survival is up to 41%, almost half
of the patients suffer from treatment-related adverse
effects such as stenosis, fistulas, hemorrhage of the blad-
der, and/or necrosis [37]. Furthermore, worse outcome at
extension of the tumor over the whole urethra has to be
taken into consideration [37]. A recent single-center study
by Derksen et al [21] demonstrated better survival in
surgically treated patients than in RT-treated patients,
although no statistical analysis was given. A population-
based NCDB study by Son et al [18] revealed no benefits in
OS for patients treated with surgery combined with RT for
stage T1-T2, limiting recommendation for a combined
therapeutic approach. The NCCN recommends chemora-
diotherapy in T2 patients as an alternative to surgery;
however, currently available data are sparse and mostly
restricted to case reports [23].
3.3. Treatment of locally advanced PUC
According to NCCN guidelines, primary treatment of
patients with unsuspicious LNs consists of chemoradiation
(CRT) and possibly surgery, neoadjuvant CHT with conso-
lidative surgery, or RT monotherapy. At clinically positive LN
metastasis, consolidative surgery is considered optional in
combination with CHT and/or RT [23].
Table 2 – Baseline characteristics, treatment, and outcomes of included studies investigating urothelial cancer of the prostatic urethra.
Author and year N Study
design
Stage, n (%) Treatment Survival rate (%) Median survival
time (mo)
Important findings NOS
Gofrit et al
(2009) [58]
20 Pts. without stromal
invasion, tumor
extension of
bladder cancer, or
previous MIBC
1988–2005
NR 6/12 wk BCG therapy + TURP Only prostatic:
5-yr RFS: 90%
Prostatic urethra and
bladder:
5-yr RFS: 30%
NR Higher complete
response rates
compared with
pooled data of
studies with BCG
therapy only (95.3%
vs 66%; p < 0.001)
when analyzing
prostatic invasion
only; no difference
when comparing
pts. with tumor in
bladder and
prostatic urethra
6
Ichihara et al
(2014) [59]
46 Pts.
treated
with RC
1990–
2016
Stage of bladder
cancer:
T1: 11 (24)
T2: 7 (15)
T3: 6 (13)
T4: 22 (48)
RC  chemotherapy
(MVAC)
Contiguous patterna:
5-yr OS: 34.4%
Noncontiguous:
5-yr OS: 50.9%
NR Stromal invasion (HR 6.82; p
= 0.04) and lymph node metastasis
(HR 6.97; p = 0.03) associated with
worse OS in MVAC
7
Knoedler et al
(2014) [60]
201 Pts.
treated
with RC
1980–
2006
Stage of urothelial
cancer of prostatic
urethra:
Tis: 93 (46)
T2: 43 (21)
T4a: 66 (32)
Stage of bladder
cancer:
T1: 82 (40)
T2: 40 (20)
T3: 16 (8)
Associated CIS: 33
(16)
RC  chemotherapy 5-yr local RFS:
-Tis: 55%
-T2: 71%
-T4a: 67%
5-yr CSS total:
-Tis: 73%
-T2: 57%
-T4a: 21%
5-yr CSS prostatic only:
-Tis: 83%
-T2: 73%
5-yr CSS + conc. bladder cancer
only:
-Tis: 58%
-T2: 17%
5-yr OS:
-Tis: 54%
-T2: 51%
-T4a: 15%
NR In multivariable analysis, higher
prostatic tumor stage (HR 2.17; p
= 0.009), lymph node invasion (HR
2.06; p = 0.003), and concurrent
bladder cancer (HR 4.50; p <
0.001) associated with worse CSS
7
BCG = bacillus Calmètte-Guerin; CIS = carcinoma in situ; HR = hazard ratio; MIBC = muscle-invasive bladder cancer; MVAC methotrexate, vinblastine, doxorubicin, and cisplatin; NR = not reported; NOS = Newcastle-Ottawa
Score; OS = Overall Survival; pts. = patients; RC = radical cystoprostatectomy; RFS = recurrence-free survival; TURP = transurethral resection of the prostate.
a Contiguous pattern was defined as T4 stadium and represented direct invasion of bladder cancer into the prostate.
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Fig. 2 – Suggested disease management of primary urethral carcinoma.
AC = adenocarcinoma; BCG = bacillus-Calmètte-Guerin therapy; CGI = cisplatin, gemcitabine, and ifosfamide; CT = computer tomography; 5-FU = 5-
fluorouracil; Gem-FLP = gemcitabine, 5-fluorouracil, leucovorin, and cisplatin; IL-2 = interleukin-2; ITP = ifosfamide, paclitaxel, and cisplatin; MMC =
mitomycin; MRI = magnetic resonance imaging; MVAC = methotrexate, vinblastine, doxorubicin, and cisplatin; N0 = no lymph node metastasis; N+ =
lymph node metastasis; PUC = primary urethral carcinoma; RCU = radical cyst(oprostat)ectomy with total urethrectomy; RT = radiotherapy;
SCC = squamous cell carcinoma; UC = urothelial carcinoma.
acT2cN0 should receive 66–70 Gy external beam radiation therapy (EBRT) to the tumor with possible prophylactic treatment of regional lymph nodes.
N + should receive 45–50 Gy EBRT to the tumor (boost to 66–70 Gy if possible) and regional lymph nodes according to location (boost to 54–66 Gy if
possible). Concurrent chemotherapy according to bladder cancer regimens should be considered. In females, EBRT with 50–55 Gy to the tumor (with a
boost of 10–15 Gy if possible) and the lymph nodes has been proposed.
b45–50.4 Gy EBRT to resection bed, and inguinal and pelvic lymph nodes. Boost resection margins and extranodal extensions to 54–60 Gy and areas of
gross residual disease to 66–70 Gy EBRT. Concurrent chemotherapy according to bladder cancer regimens should be considered.
c66–74 Gy EBRT to gross disease in suspected areas of recurrence (up to 74 Gy for larger tumors and non-UC) and, if possible, 45–50.4 Gy to regional
lymph nodes.
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ciplinary disease management, suggestions for curative CRT
for SCC and platinum-based neoadjuvant CHT for other
histological subtypes are weak [22].
3.3.1. Surgery for the primary tumor
Advanced PUC requires a radical surgical approach, often
consisting of radical cyst(oprostat)ectomy with totalurethrectomy (RCU) or a (partial) penectomy. Other surgical
procedures such as anterior pelvic exenteration in women
have also been reported [13]. Historical cohorts report long-
term OS rates of 11–42% in women and 0–38% in men with
advanced PUC [40]. In several smaller studies, males who
underwent pelvic exenteration combined with en bloc pub-
ectomy including the genitourethral diaphragm (possibly
with lymphadenectomy and RT) had fewer recurrences
Table 3 – TNM classification and 2016 WHO grading for primary urethral carcinoma.
T—primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Urethra (male and female)
Ta Noninvasive papillary, polypoid, or verrucous carcinoma
Tis Carcinoma in situ
T1 Tumor invades subepithelial connective tissue
T2 Tumor invades any of the following: corpus spongiosum, prostate, periurethral
muscle
T3 Tumor invades any of the following: corpus cavernosum, beyond prostatic
capsule, anterior vagina, bladder neck (extraprostatic extension)
T4 Tumor invades other adjacent organs (invasion of the bladder)
Urothelial (transitional cell) carcinoma of the prostate
Tis pu Carcinoma in situ, involvement of prostatic urethra
Tis pd Carcinoma in situ, involvement of prostatic ducts
T1 Tumor invades subepithelial connective tissue (for tumors involving prostatic
urethra only)
T2 Tumor invades any of the following: prostatic stroma, corpus spongiosum,
periurethral muscle
T3 Tumor invades any of the following: corpus cavernosum, beyond prostatic
capsule, bladder neck (extraprostatic extension)
T4 Tumor invades other adjacent organs (invasion of the bladder or rectum)
N—regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single lymph node
N2 Metastasis in multiple lymph nodes
M—distant metastasis
M0 No distant metastasis
M1 Distant metastasis
Grading of urothelial urethral carcinoma
PUNLMP Papillary urothelial neoplasm of low malignant potential
Low grade Well differentiated
High grade Poorly differentiated
Grading of nonurothelial urethral carcinoma
Gx Tumor grade not assessable
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
TNM = tumor-node-metastasis; WHO = World Health Organization.
E U R O P E A N U R O L O G Y F O C U S 5 ( 2 0 1 9 ) 7 2 2 – 7 3 4730(24%) than patients without en bloc resection in proximal
PUC (63%) [41,42]. However, with no unified study design
preventing selection bias, the results have to be interpreted
with care. Indeed, a retrospective cohort study by Dalbagni
et al [43] reported RFS of 51% after 5 yr for patients treated
with surgery only, with only 56% being metastasis free. Only
a few cases of advanced PUC have been managed with
penile/urethral preservation [35,41]. Nevertheless, since
the quality of life is generally gravely decreased after radical
surgical approaches, future research should aim at identi-
fying a personalized multimodal approach to advanced PUC
to improve oncological results as well as preserving genital
and urethral integrity.
3.3.2. Lymphadenectomy
Similar to UC of the other locations, pathological LN metas-
tasis is an independent prognostic factor for worse OS in
PUC patients even with no metastasis at diagnosis (p <
0.001) [31,44]. Patients with pathological LN metastasis
have been reported to have significantly lower RFS rates
and shorter CSS after 5 yr (overall p = 0.01) [38]. The differ-
ential lymph drainage of anterior PUC into inguinal LN andof tumors located in the posterior urethra to the pelvic LNs
has to be taken into consideration for clinical decision
making [45]. At RCU, a lymphadenectomy template similar
to bladder cancer can be performed, including all pelvic LNs
[46]. However, due to the drainage of PUC in distal location
into the inguinal LNs, a combined inguinal and pelvic
lymphadenectomy is advised, especially in PUC that reaches
beyond the bulbous into the pendulous urethra. If the PUC is
located solely in the distal pendulous urethra, sole resection
of the superficial and deep inguinal LNs can be considered.
Owing to the difficulty in assessing LN status clinically by
current imaging tools, prophylactic treatment has been
suggested [35]. However, due to the scarcity of data, no
definite statement can be made regarding the therapeutic
value of an adequate lymphadenectomy template in
patients with PUC.
3.3.3. Multimodal treatment
While still underused today, multimodal therapy (MMT),
consisting of a combination of surgery, CHT, and/or RT, is
probably necessary for most patients with advanced PUC.
Peyton et al [16] could not prove significant improvement in
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those treated with monotherapy (ie, median OS of 36 vs
16 mo and median RFS of 58 vs 16 mo), likely due to its small
cohort size.
Several smaller studies have reported promising OS of up
to 83% after 1 yr of CRT [41]. However, high heterogeneity in
treatment regimens and study populations limits interpre-
tation of the results. For example, Thyavihally et al [47]
showed median 5-yr OS and 5-yr RFS of only 49% and 23%,
respectively. If systemic CHT is provided before surgery,
response to this treatment is essential for sustained OS
[48]. In the follow-up of combined RT and concurrent
CHT with 5-fluorouracil and mitomycin, all nonresponders
died during the follow-up, even those who underwent
salvage surgery. Of 15 patients with an objective response,
four out of five patients who suffered disease recurrence
were alive 5 yr after salvage surgery [48]. These findings
suggest a beneficial effect of MMT on oncological outcomes.
Furthermore, concurrent RT and CHT may help in genital
preservation strategies similarly to bladder cancer
[41,49]. However, outcomes for patients with advanced
PUC are still relatively poor despite MMT. Well-designed
prospective studies are needed to assess the optimal treat-
ment strategy, and benefits and shortcomings of different
modalities. Until then, our strategy has been to offer MMT,
consisting of surgery and neoadjuvant CHT, as building
blocks that can be enhanced in select cases with adjuvant
RT, to all patients with advanced PUC, with the hope of
resulting in durable local and distant disease control.
3.3.4. Influence of RT on survival outcomes
A positive effect of the combination of surgery and RT
compared with monotherapy has been reported previously
[41]. While surgery alone was associated with better CSS
than RT alone in the SEER studies of Rabbani [17] (p = 0.018)
and Champ et al [12] (p = 0.001), Wei et al [19] found
surgery to be an independent factor for better OS and
CSS in women treated with RT (p = 0.003). Furthermore,
Son et al [18] reported that in the NCDB cohort, the absence
of local therapy (surgery and/or RT) was an independent
factor for worse OS (no p value reported). In addition, the
combination of surgery and adjuvant RT resulted in the best
OS probabilities (p < 0.01). Interestingly, the use of both RT
alone (hazard ratio [HR] 0.20; 95% confidence interval [CI],
0.07–0.60) and in combination with surgery (HR 0.27; 95%
CI, 0.10–0.75) were associated with better OS in patients
with AC histology, while CHT alone was associated with
worse OS (HR 3.43; 95% CI, 1.40–8.39; p < 0.01). In UC
patients, adjuvant RT improved OS as well (HR 0.45; 95% CI,
0.26–0.77; p < 0.01), while there was no difference of OS in
patients with SCC who received adjuvant RT. From the
investigated studies, it seems that RT monotherapy is infe-
rior to a combined approach with surgery. Indeed, past
studies reported 5-yr OS of only 0–25% in males and up
to 50% in females treated with RT monotherapy [40]. More-
over, 2-yr recurrence rates of 95% have been reported under
RT monotherapy, with a limited local control of under 50% at
5 yr [42]. Gakis et al [15] observed a more frequent use of
palliative CHT in patients with initial RT, possibly indicatinga higher risk of metastasis. These findings suggest that a
combination with other treatment modalities is preferable
to improve OS in patients, especially in patients with AC and
UC histologies.
3.3.5. Influence of systemic CHT on survival outcomes
CHT regimens for PUC depend on the underlying histology.
While a platinum-based therapy is preferable for UC and
SCC, chemotherapeutic strategies for AC differ based on the
origin of cancer [50]. Therefore, a correct therapy schema is
difficult to assess for PUC, especially because of a possible
overlap in histological features [9]. Platinum-based therapy
is the most common CHT already proposed in an early,
larger cohort study by Dinney et al [42], where prolonged
survival for metastatic patients with CHT was reported.
Similar to bladder cancer [51], perioperative CHT seems
to improve oncological survival. Reported alternatives for
patients who are unable to receive a platinum-based CHT
are rare and consist of mitomycin/5-fluorouracil with or
without RT, paclitaxel with or without gemcitabine, car-
mustin/interleukin-2, or dacarbazine [14,16]. Mitomycin
and 5-fluorouracil in combination with concurrent RT
showed promising results, with more than half of the
patients being disease free after 5 yr [48].
Median OS of patients treated with platinum-based CHT
in the single-center study of Dayyani et al [13] was 25.6 mo,
which is shorter than the rate reported for the complete
cohort (31.7 mo). However, the median OS of alive patients
at the median follow-up was 42.0 mo with a 3-yr survival
rate of 50%, supporting the beneficial impact of platinum-
based CHT [13]. Potential CHT regimes included cisplatin,
gemcitabine, and ifosfamide (CGI); ifosfamide, paclitaxel,
and cisplatin (ITP); or methotrexate, vinblastine, doxorubi-
cin, and cisplatin (MVAC) for UC patients; CGI or ITP for SCC
patients; and gemcitabine, 5-fluorouracil, leucovorin, and
cisplatin for AC patients. Resection of the primary tumor
together with perioperative CHT resulted in longer OS than
CHT alone (p = 0.02) [13].
Finally, in a large study based on a multi-institutional
cohort, Gakis et al [14] have shown that 3-yr OS and PFS
were significantly improved by neoadjuvant CHT with or
without adjuvant therapy, compared with adjuvant therapy,
only in patients with advanced disease(p = 0.022 and p =
0.024, respectively). Although this implies superiority of
neoadjuvant treatment to adjuvant treatment, evidence is
vague at best.
3.4. Therapy for recurrent PUC
Local or distant recurrence after initial therapy occurs in up
to 71% of patients after 5 yr, with median 5-yr RFS of 24–63%
[38,41]. Of note, recurrence occurs more often in proximal
than in distal location (50–57% vs 8–33%) [42,52]. While
prevention of recurrence and progression is essential for
improving OS, investigation of salvage therapy after recur-
rence is sparse. The EAU guidelines suggest RT or surgery,
while the NCCN considers systemic (mono)therapy as well
[22,23]. Peyton et al [16] reported no difference in OS
between patients presenting with metastasis and those
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therapy (p = 0.56).
In the largest study to date, Gakis et al [15] stratified
outcomes according to therapy for disease recurrence. Clin-
ical LN metastasis and distal tumor location were indepen-
dent prognostic factors for recurrence. Only extraurethral
recurrence significantly affected 3-yr OS compared with no
recurrence (48.5% vs 86.5%, p = 0.002), while a solitary or
concomitant recurrence did not (74.5%). In contrast to these
results, Peyton et al [16] reported that salvage surgery or
CRT improved 3-yr OS (p < 0.001 and p = 0.045, respec-
tively) to almost match that of patients without recurrence
(p = 0.065). Interestingly, no difference in survival was
observed between different salvage therapies. However,
reasons for this can be attributed to the limited information
given by the NCDB and a focus on female nonmetastatic
patients. This strongly suggests superiority of salvage ther-
apy, albeit no specific recommendations can yet be given
regarding the best therapeutic modality.
3.5. Treatment of UC of the prostate
UC in the prostatic urethra is a rare disease and often
features concomitant bladder cancer (Table 2). Many
patients already have stromal invasion at the point of
diagnosis, which in turn affects OS, making careful assess-
ment even more important [53,54]. Historically, prognosis
for these patients was poor, with only a few 2-yr survivors
being present [53]. Owing to this, efforts have been made to
optimize therapy. A combined approach of TUR and bacillus
Calmètte-Guerin (BCG) therapy in patients with noninva-
sive disease can suffice to assure satisfactory outcomes with
complete response rates of up to 75% and 5-yr RFS rates of
90% [55–57]. This is also recommended by the current
guidelines and is in line with the findings of Gofrit et al
[58], who reported a better response rate of patients treated
with TUR of the bladder B and BCG compared with BCG
therapy only [22 23]. A thorough follow-up with cystoscopy
and urine cytology is important to identify recurrences
early, which are often best treated with radical RCU with
or without perioperative CHT [55–57].
Prostatic involvement of PUC is invasive in 7.6–16.6% of
cases and is associated with 12–48% non–muscle-invasive
concomitant bladder cancer. Both these factors were found
to be associated with worse outcomes [56,59,60]. If involve-
ment of prostatic ducts and acini is present, UC in the
prostatic urethra is often located at 5 or 7 o’clock superfi-
cially, but deeper invasion cannot be ruled out and a radical
RCU is advised [61,62]. Since LN invasion often occurs above
the iliac bifurcation and possibly affects OS, platinum-based
neoadjuvant CHT as well as neoadjuvant RT has been pro-
posed in the past. This combination has resulted in
improved OS, while recommendations on adjuvant therapy
cannot be made yet [56].
An extended pelvic lymphadenectomy is strongly recom-
mended in patients with nodal invasion, those with disease
recurrence, or those who did not respond to BCG therapy
[22,56]. However, most current studies include patients
with concomitant bladder cancer, making a properassessment of the biological and clinical impact of UC of
the prostatic urethra on survival difficult.
4. Conclusions
PUC is a rare malignancy with weak evidence mostly from
studies with few patients. Location, sex, and nodal involve-
ment affect therapy and prognosis, and have to be taken into
consideration to achieve the best disease management.
Localized, low-grade disease can be treated with penile-
sparing surgery in males, while female patients require
urethrectomy with extensive margins. Positive margins
result in significantly worse survival and should be avoided
at all costs. RT should be offered only to female patients in
whom surgery is refused or impossible.
In locally advanced PUC, surgery usually consists of
(partial) penectomy or RCU. Anterior pelvic exenteration
can be improved by en bloc resection. LN metastasis is
associated with worse survival and lymphadenectomy
should be considered prophylactically in advanced PUC
patients, as it informs about tumor stage and has, poten-
tially, a therapeutic benefit.
Advanced disease should be treated with MMT to increase
OS and RFS. In some cases, CRT can even result in genital
preservation. While RT improves outcome especially in
patients with AC and UC histology, a multimodal approach
is beneficial. Platinum-based CHTcan improve OS and PFS, and
should be used in a neoadjuvant setting followed by surgery.
Research on recurrence is still sparse. However, salvage
therapy is likely to improve oncological outcomes, warranting
a multidisciplinary approach to therapy based on evidence.
UC of the prostatic urethra is rare and often occurs with
concomitant bladder cancer. If noninvasive, a TUR and
consecutive BCG therapy can be attempted with curative
intent. Carcinomas with stromal invasion and BCG-unre-
sponsive patients with recurrence require a radical surgical
approach with RCU and lymphadenectomy. Neoadjuvant RT
or platinum-based CHT should be considered in all patients
with advanced disease.
PUC is still largely under-researched, rendering an ade-
quate recommendation for therapy difficult. Future
research should focus on multi-institutional studies to
increase population sizes, and improve our knowledge
and understanding of this malignancy.
Author contributions: Shahrokh F. Shariat had full access to all the data
in the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Fajokvic.
Acquisition of data: Janisch.
Analysis and interpretation of data: Iwata, Kimura.
Drafting of the manuscript: Janisch.
Critical revision of the manuscript for important intellectual content:
Abufaraj, Rink, Shariat, Nyirady.
Statistical analysis: None.
Obtaining funding: None.
Administrative, technical, or material support: None.
Supervision: Shariat.
Other: None.
E U R O P E A N U R O L O G Y F O C U S 5 ( 2 0 1 9 ) 7 2 2 – 7 3 4 733Financial disclosures: Shahrokh F. Shariat certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents filed, received, or pending), are the following: Mohammad
Abufaraj was awarded a European Urological Scholarship Program grant
(EUSP/Scholarship S-01-2018).
Funding/Support and role of the sponsor: None.
References
[1] Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare
urogenital cancers in Europe. Eur J Cancer 2012;48:456–64.
[2] Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so
rare: the rare cancer burden in Europe. Eur J Cancer 2011;47:2493–
511.
[3] Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary
urethral carcinoma in the United States. Urology 2006;68:1164–8.
[4] Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly.
Urol Oncol 2009;27:653–67.
[5] Van de Voorde W, Meertens B, Baert L, Lauweryns J. Urethral
squamous cell carcinoma associated with urethral stricture and
urethroplasty. Eur J Surg Oncol 1994;20:478–83.
[6] Thomas AA, Rackley RR, Lee U, Goldman HB, Vasavada SP, Hansel DE.
Urethral diverticula in 90 female patients: a study with emphasis on
neoplastic alterations. J Urol 2008;180:2463–7.
[7] Cupp MR, Malek RS, Goellner JR, Espy MJ, Smith TF. Detection of
human papillomavirus DNA in primary squamous cell carcinoma of
the male urethra. Urology 1996;48:551–5.
[8] Guo H, Peng X, Jin C, Wang L, Chen F, Sa Y. Lichen sclerosus
accompanied by urethral squamous cell carcinoma: a retrospective
study from a urethral referral center. Am J Mens Health
2018;12:1692–9.
[9] Zhang M, Adeniran AJ, Vikram R, et al. Carcinoma of the urethra.
Hum Pathol 2018;72:35–44.
[10] Wells G, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS)
for assessing the quality of non-randomized studies in meta-analysis.
Web site http://www.ohri.ca/programs/clinical_epidemiology/
nosgen.pdf Ottawa Hospital Research Institute; 2000.
[11] Cahn DB, Handorf E, Ristau BT, et al. Contemporary practice patterns
and survival outcomes for locally advanced urethral malignancies: a
National Cancer Database analysis. Urol Oncol 2017;35(670):
e15–21.
[12] Champ CE, Hegarty SE, Shen X, et al. Prognostic factors and out-
comes after definitive treatment of female urethral cancer: a pop-
ulation-based analysis. Urology 2012;80:374–81.
[13] Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro
LC. Retrospective analysis of survival outcomes and the role of
cisplatin-based chemotherapy in patients with urethral carcinomas
referred to medical oncologists. Urol Oncol 2013;31:1171–7.
[14] Gakis G, Morgan TM, Daneshmand S, et al. Impact of perioperative
chemotherapy on survival in patients with advanced primary ure-
thral cancer: results of the international collaboration on primary
urethral carcinoma. Ann Oncol 2015;26:1754–9.
[15] Gakis G, Schubert T, Morgan TM, et al. The prognostic effect of
salvage surgery and radiotherapy in patients with recurrent pri-
mary urethral carcinoma. Urol Oncol 2018;36(10), e7–4.
[16] Peyton CC, Azizi M, Chipollini J, et al. Survival outcomes associated
with female primary urethral carcinoma: review of a single insti-
tutional experience. Clin Genitourin Cancer 2018;16, e1003–13.[17] Rabbani F. Prognostic factors in male urethral cancer. Cancer
2011;117:2426–34.
[18] Son CH, Liauw SL, Hasan Y, Solanki AA. Optimizing the role of
surgery and radiation therapy in urethral cancer based on histology
and disease extent. Int J Radiat Oncol Biol Phys 2018;102:304–13.
[19] Wei Y, Wu YP, Xu N, et al. Sex-related differences in clinicopatho-
logical features and survival of patients with primary urethral
carcinoma: a population-based study. OncoTargets Ther
2017;10:3381–9.
[20] Moher D, Shamseer L, Clarke M, et al. Preferred Reporting Items for
Systematic Review and Meta-analysis protocols (PRISMA-P)
2015 statement. Syst Rev 2015;4:1.
[21] Derksen JW, Visser O, de la Riviere GB, Meuleman EJ, Heldeweg EA,
Lagerveld BW. Primary urethral carcinoma in females: an epidemi-
ologic study on demographical factors, histological types, tumour
stage and survival. World J Urol 2013;31:147–53.
[22] Gakis G, Witjes JA, Compérat E, et al. EAU guidelines on primary
urethral carcinoma. Eur Urol 2013;64:823–30.
[23] Spiess PE, Agarwal N, Bangs R, et al. Bladder cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw 2017;15:1240–67.
[24] Comperat E, Varinot J. Immunochemical and molecular assessment
of urothelial neoplasms and aspects of the 2016 World Health
Organization classification. Histopathology 2016;69:717–26.
[25] Brierley DJ, Gospodarowicz K, Wittekind C, editors. TNM classifica-
tion of malignant tumours. ed. 8. UICC International Union Against
Cancer. Wiley/Blackwell; 2017. p. 208.
[26] Gheiler EL, Tefilli MV, Tiguert R, de Oliveira JG, Pontes JE, Wood Jr DP.
Management of primary urethral cancer. Urology 1998;52:487–93.
[27] Touijer AK, Dalbagni G. Role of voided urine cytology in diagnosing
primary urethral carcinoma. Urology 2004;63:33–5.
[28] Donat SM, Wei DC, McGuire MS, Herr HW. The efficacy of trans-
urethral biopsy for predicting the long-term clinical impact of
prostatic invasive bladder cancer. J Urol 2001;165:1580–4.
[29] Kakizoe T, Tobisu K. Transitional cell carcinoma of the urethra in
men and women associated with bladder cancer. Jpn J Clin Oncol
1998;28:357–9.
[30] Gakis G, Efstathiou JA, Daneshmand S, et al. Oncological outcomes
of patients with concomitant bladder and urethral carcinoma. Urol
Int 2016;97:134–41.
[31] Gakis G, Morgan TM, Efstathiou JA, et al. Prognostic factors and
outcomes in primary urethral cancer: results from the international
collaboration on primary urethral carcinoma. World J Urol
2016;34:97–103.
[32] Itani M, Kielar A, Menias CO, et al. MRI of female urethra and
periurethral pathologies. Int Urogynecol J 2016;27:195–204.
[33] Smith Y, Hadway P, Ahmed S, Perry MJ, Corbishley CM, Watkin NA.
Penile-preserving surgery for male distal urethral carcinoma. BJU
Int 2007;100:82–7.
[34] Torbrand C, Hakansson U, Ehrnstrom R, Liedberg F. Diagnosing
distal urethral carcinomas in men might be only the tip of the
iceberg. Clin Genitourin Cancer 2017;15:e1131–1135.
[35] Karnes RJ, Breau RH, Lightner DJ. Surgery for urethral cancer. Urol
Clin North Am 2010;37:445–57.
[36] Kang M, Jeong CW, Kwak C, Kim HH, Ku JH. Survival outcomes and
predictive factors for female urethral cancer: Long-term experience
with Korean patients. J Korean Med Sci 2015;30:1143–9.
[37] Garden AS, Zagars GK, Delclos L. Primary carcinoma of the female
urethra. Results of radiation therapy. Cancer 1993;71:3102–8.
[38] Dimarco DS, Dimarco CS, Zincke H, et al. Surgical treatment for local
control of female urethral carcinoma. Urol Oncol 2004;22:404–9.
[39] Ahmed K, Dasgupta R, Vats A, et al. Urethral diverticular carcinoma:
an overview of current trends in diagnosis and management. Int
Urol Nephrol 2010;42:331–41.
E U R O P E A N U R O L O G Y F O C U S 5 ( 2 0 1 9 ) 7 2 2 – 7 3 4734[40] Zinman LN, Vanni AJ. Management of proximal primary urethral
cancer: should multidisciplinary therapy be the gold standard? Urol
Clin North Am 2016;43:505–13.
[41] Dayyani F, Hoffman K, Eifel P, et al. Management of advanced
primary urethral carcinomas. BJU Int 2014;114:25–31.
[42] Dinney CPN, Johnson DE, Swanson DA, Babaian RJ, Von Eschenbach
AC. Therapy and prognosis for male anterior urethral carcinoma: an
update. Urology 1994;43:506–14.
[43] Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Male urethral carci-
noma: analysis of treatment outcome. Urology 1999;53:1126–32.
[44] Lughezzani G, Jeldres C, Isbarn H, et al. A critical appraisal of the
value of lymph node dissection at nephroureterectomy for upper
tract urothelial carcinoma. Urology 2010;75:118–24.
[45] Ray B, Canto AR, Whitmore WF. Experience with primary carcinoma
of the male urethra. J Urol 1977;117:591–4.
[46] Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-
invasive urothelial carcinoma of the bladder: update 2016. Eur Urol
2017;71:447–61.
[47] Thyavihally YB, Tongaonkar HB, Srivastava SK, Mahantshetty U,
Kumar P, Raibhattanavar SG. Clinical outcome of 36 male patients
with primary urethral carcinoma: a single center experience. Int J
Urol 2006;13:716–20.
[48] Cohen MS, Triaca V, Billmeyer B, et al. Coordinated chemoradiation
therapy with genital preservation for the treatment of primary
invasive carcinoma of the male urethra. J Urol 2008;179:536–41.
[49] Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of
bladder sparing with trimodal therapy in muscle-invasive bladder
cancer: a systematic review. Eur Urol 2014;66:120–37.
[50] DeConti RC. Chemotherapy of squamous cell carcinoma of the skin.
Semin Oncol 2012;39:145–9.
[51] Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of
neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur
Urol 2015;67:241–9.
[52] Dalbagni G, Zhang ZF, Lacombe L, Herr HW. Female urethral carci-
noma: an analysis of treatment outcome and a plea for a standard-
ized management strategy. Br J Urol 1998;82:835–41.[53] Matzkin H, Soloway MS, Hardeman S. Transitional cell carcinoma of
the prostate. J Urol 1991;146:1207–12.
[54] Njinou Ngninkeu B, Lorge F, Moulin P, Jamart J, Van Cangh PJ.
Transitional cell carcinoma involving the prostate: a clinico-
pathological retrospective study of 76 cases. J Urol 2003;
169:149–52.
[55] Palou Redorta J, Schatteman P, Huguet Perez J, et al. Intravesical
instillations with bacillus Calmette-Guerin for the treatment of
carcinoma in situ involving prostatic ducts. Eur Urol 2006;49:
834–838, discussion 838.
[56] Palou J, Baniel J, Klotz L, et al. Urothelial carcinoma of the prostate.
Urology 2007;69(1 Suppl):50–61.
[57] Schellhammer PF, Ladaga LE, Moriarty RP. Intravesical bacillus
Calmette-Guerin for treatment of superficial transitional cell carci-
noma of the prostatic urethra in association with carcinoma of the
bladder. J Urol 1995;153:53–6.
[58] Gofrit ON, Pode D, Pizov G, Zorn KC, Katz R, Shapiro A. Prostatic
urothelial carcinoma: is transurethral prostatectomy necessary
before bacillus Calmette-Guerin immunotherapy? BJU Int
2009;103:905–8.
[59] Ichihara K, Masumori N, Kitamura H, Hasegawa T, Tsukamoto T.
Clinical outcomes of urothelial carcinoma of the prostate
detected in radical cystectomy specimens. Int J Clin Oncol
2014;19:152–6.
[60] Knoedler JJ, Boorjian SA, Tollefson MK, et al. Urothelial carcinoma
involving the prostate: the association of revised tumour stage and
coexistent bladder cancer with survival after radical cystectomy.
BJU Int 2014;114:832–6.
[61] Sakamoto N, Tsuneyoshi M, Naito S, Kumazawa J. An adequate
sampling of the prostate to identify prostatic involvement by
urothelial carcinoma in bladder cancer patients. J Urol
1993;149:318–21.
[62] Solsona E, Iborra I, Ricos JV, Monros JL, Casanova JL, Almenar S. The
prostate involvement as prognostic factor in patients with superfi-
cial bladder tumors. J Urol 1995;154:1710–3.
